|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.87/-0.68
|
企业价值
902.70M
|
资产负债 |
每股账面净值
4.46
|
现金流量 |
现金流量率
--
|
损益表 |
收益
7.50M
|
每股收益
0.07
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/15 06:49 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. |